432047-72-8Relevant academic research and scientific papers
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration
Dziadulewicz, Edward K.,Bevan, Stuart J.,Brain, Christopher T.,Coote, Paul R.,Culshaw, Andrew J.,Davis, Andrew J.,Edwards, Lee J.,Fisher, Adrian J.,Fox, Alyson J.,Gentry, Clive,Groarke, Alex,Hart, Terance W.,Huber, Werner,James, Iain F.,Kesingland, Adam,La Vecchia, Luigi,Loong, Yvonne,Lyothier, Isabelle,McNair, Kara,O'Farrell, Cathal,Peacock, Marcus,Portmann, Robert,Schopfer, Ulrich,Yaqoob, Mohammed,Zadrobilek, Jiri
, p. 3851 - 3856 (2007)
Selective activation of peripheral cannabinoid CB1 receptors has the potential to become a valuable therapy for chronic pain conditions as long as central nervous system effects are attenuated. A new class of cannabinoid ligands was rationally
NEW USE IN GASTROINTESTINAL DISORDERS
-
Page/Page column 12, (2008/06/13)
The present invention relates to the use of a compound of formula I for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of a compound of formula I for the treatment of gastro-esophageal reflux disease, as well as for the treatment of regurgitation.
Naphthalene derivatives
-
, (2008/06/13)
The present invention relates to novel naphthalene derivatives of formula (I), wherein R1, R2, R3 and X are as defined in the description, and preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.